Enveric Biosciences, Inc. - Common Stock (NQ:ENVB)

1.430 -0.030 (-2.05%)

Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Enveric Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

These stocks are moving in today's pre-market session ↗

January 31, 2025

Before the opening bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

Why Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗

January 31, 2025

Via Benzinga

Enveric Biosciences Announces Pricing of $5 Million Public Offering

January 30, 2025

From Enveric Biosciences, Inc.

Via Business Wire

What's going on in today's after hours session ↗

January 30, 2025

After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office

January 30, 2025

From Enveric Biosciences

Via Business Wire

Let's take a look at the stocks that are in motion in today's session. ↗

January 29, 2025

Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes.

Via Chartmill

Here are the top movers in Wednesday's session. ↗

January 29, 2025

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

January 29, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

January 07, 2025

Via Benzinga

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”

January 06, 2025

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds

December 02, 2024

From Enveric Biosciences

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 27, 2024

Via Benzinga

Enveric Biosciences Advances Non-Hallucinogenic DMT Analog Drug With Promising Preclinical Results ↗

November 25, 2024

Via Benzinga

Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior

November 25, 2024

From Enveric Biosciences, Inc.

Via Business Wire

Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket ↗

November 19, 2024

Via Benzinga

Enveric Biosciences Trims Losses, Eyes Key Drug Approval For Difficult-To-Treat Mental Health Disorders ↗

November 18, 2024

Via Benzinga

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results

November 14, 2024

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Out-Licenses Key Program To MycoMedica In $62M Deal ↗

November 12, 2024

Enveric licenses EB-002 to MycoMedica for neuropsychiatric treatment, focusing on EB-003's development with potential milestones up to $62M.

Via Benzinga

Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002

November 12, 2024

From Enveric Biosciences, Inc.

Via Business Wire

Enveric Biosciences Announces Broad Range of Patent Issuances

November 04, 2024

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Expands Mental Health Patent Portfolio With 5 New Additions ↗

November 04, 2024

Enveric Biosciences expands its patent portfolio with five new U.S. patents, supporting treatments for depression, anxiety and epilepsy.

Via Benzinga

Topics Intellectual Property

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 23, 2024

Via Benzinga

Enveric Biosciences Advances Testing Of Its Non-Hallucinogenic Psychedelic ↗

October 15, 2024

Enveric Biosciences announces positive preclinical results for EB-003, showcasing its potential as a safe and effective treatment for mental health disorders.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 15, 2024

Via Benzinga

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

October 15, 2024

From Enveric Biosciences

Via Business Wire

Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies ↗

October 04, 2024

Companies are developing safer, targeted psychedelic therapies aimed at reducing risks and improving mental health treatment options.

Via Benzinga

Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop

September 26, 2024

From Enveric Biosciences

Via Business Wire

Non-Hallucinogenic Psychedelic Treatment For Anxiety And Depression In Pre-Clinical Models: Enveric Biosciences' Breakthrough Research ↗

September 25, 2024

Psychedelics biotech company Enveric Biosciences (NASDAQ: ENVB) has presented research highlighting the company's lead compound, EB-003 at the 7th Neuropsychiatric Drug Summit. The conference is being...

Via Benzinga

Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit

September 25, 2024

From Enveric Biosciences

Via Business Wire

Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

September 04, 2024

From Enveric Biosciences

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.